Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease

  • Saemi Park
  • Han Joo ChoEmail author
  • Dong Won Lee
  • Chul Gu Kim
  • Jong Woo Kim
Retinal Disorders



To evaluate the efficacy of intravitreal bevacizumab injections combined with laser photocoagulation in the treatment of adult-onset Coats’ disease.


Thirteen eyes of 13 patients suffering from adult-onset Coats’ disease were retrospectively included and analyzed. All patients were treated at baseline using intravitreal bevacizumab injections combined with laser photocoagulation. Follow-up treatment was performed as necessary.


The mean age of the subjects was 40.3 years, and the mean follow-up period was 24.8 months. The mean number of bevacizumab injections was 2.69, and the mean number of laser treatment sessions was 1.68. The mean baseline best-corrected visual acuity (BCVA) was 0.72 logarithm of the minimum angle of resolution (logMAR; 20/104 Snellen equivalent), while the mean BCVA at the final visit was 0.68 logMAR (20/95; P = 0.548). In three patients (23.0 %), BCVA had improved by more than 3 lines, and seven patients (54.0 %) showed stable BCVA (changes within 2 lines of visual acuity) after treatment. The mean central foveal thickness improved significantly, from 473 μm at baseline to 288 μm at the final visit (P = 0.023). Final BCVA was significantly correlated with a baseline BCVA (P < 0.001; ρ = 0.882). The final BCVA of patients who had subfoveal hard exudates at baseline was significantly worse than that of patients without such exudates (P = 0.005).


Intravitreal bevacizumab injection combined with laser photocoagulation may be an effective treatment option for adult-onset Coats’ disease. Both poor initial BCVA and the occurrence of subfoveal hard exudates at baseline were associated with poor prognosis and poor therapeutic response.


Bevacizumab Coat’s disease Laser photocoagulation Vascular endothelial growth factor 


Compliance with ethical standards


No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Shields JA, Shields CL, Honavar SG, Demirci H (2001) Clinical variations and complications of coats diseased in 150 cases: the 200 Sanford Gifford memorial lecture. Am J Ophthalmol 131:561–571CrossRefPubMedGoogle Scholar
  2. 2.
    Smithen LM, Brown GC, Brucker AJ, Yannuzzi LA, Klais CM, Spaide RF (2005) Coats’ disease diagnosed in adulthood. Ophthalmology 112:1072–1078CrossRefPubMedGoogle Scholar
  3. 3.
    Lai CH, Kuo HK, Wu PC, Kuo ML, Chen YJ (2007) Manifestation of coats’ disease by age in Taiwan. Clin Exp Ophthalmol 35:361–365CrossRefGoogle Scholar
  4. 4.
    Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG (2014) Current management of coats disease. Surv Ophthalmol 59:30–46CrossRefPubMedGoogle Scholar
  5. 5.
    Zheng XX, Jiang YR (2014) The effect of intravitreal bevacizumab injection as the initial treatment for coats’ disease. Graefes Arch Clin Exp Ophthalmol 252:35–42CrossRefPubMedGoogle Scholar
  6. 6.
    Lin CJ, Hwang JF, Chen YT, Chen SN (2010) The effect of intravitreal bevacizumab in the treatment of coats disease in children. Retina 30:617–622CrossRefPubMedGoogle Scholar
  7. 7.
    Ghorbanian S, Jaulim A, Chartziralli IP (2012) Diagnosis and treatment of coats’ disease: a review of the literature. Ophthalmologica 227:175–182CrossRefPubMedGoogle Scholar
  8. 8.
    Galliard MC, Mataftsi A, Balmer A, Houghton S, Munier FL (2014) Ranibizumab in the management of advanced coats disease stages 3B and 4. Retina 34:2275–2281CrossRefGoogle Scholar
  9. 9.
    Wang KY, Cheng CK (2011) A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset coats’ disease. J Ocul Pharmacol Ther 27:525–530CrossRefPubMedGoogle Scholar
  10. 10.
    Böhm MR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 249:1099–1101CrossRefPubMedGoogle Scholar
  11. 11.
    Kim J, Park KH, Woo SJ (2010) Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult coats’ disease: a case report. Korean J Ophthalmol 24:374–376CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhao Q, Peng XY, Chen FH et al (2014) Vascular endothelial growth factor in coats’ disease. Acta Ophthlamol 92:225–228CrossRefGoogle Scholar
  13. 13.
    Kase S, Rao NA, Yoshikawa H et al (2013) Expression of vascular endothelial growth factor in eyes with coats’ disease. Invest Ophthalmol Vis Sci 54:57–62CrossRefPubMedGoogle Scholar
  14. 14.
    He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J (2010) Elevated vascular endothelial growth factor level in coat’s disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol 248:1519–1521CrossRefPubMedGoogle Scholar
  15. 15.
    Sun Y, Jain A, Moshfeghi DM (2007) Elevated vascular endothelial growth factor levels in coats’ disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 245:1387–1388CrossRefPubMedGoogle Scholar
  16. 16.
    Domalpally A, Ip MS, Ehrlich JS (2015) Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 122:779–786CrossRefPubMedGoogle Scholar
  17. 17.
    Ramasubramanian A, Shields CL (2012) Bevacizumab for coats’ diease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96:356–359CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Saemi Park
    • 1
  • Han Joo Cho
    • 1
    Email author
  • Dong Won Lee
    • 1
  • Chul Gu Kim
    • 1
  • Jong Woo Kim
    • 1
  1. 1.Department of Ophthalmology, Kim’s Eye Hospital, Myung-Gok Eye Research InstituteKonyang University College of MedicineSeoulSouth Korea

Personalised recommendations